Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.45 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.45 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 2/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutarate SCHEMBL27964714 | 0.91 | SLC22A6 (0.50) | KDM4EMEN1KMT2AGAACYP2C9 | |
| Sebacic Acid SCHEMBL27736944 | 0.89 | TSHR (0.52) | KDM4EMEN1KMT2AGAACYP2C9 | |
| Morpholine SCHEMBL11191668 | 0.87 | FFAR3 (0.54) | KDM4EMEN1KMT2AGAACYP2C9 | |
| Morpholine SCHEMBL9162514 | 0.85 | MEN1 (0.52) | KDM4EMEN1KMT2AGAACYP2C9 | |
| Morpholine SCHEMBL4018377 | 0.84 | MEN1 (0.65) | KDM4EMEN1KMT2AGAACYP2C9 | |
| Morpholine SCHEMBL14957611 | 0.84 | MEN1 (0.65) | KDM4EMEN1KMT2AGAACYP2C9 | |
| Morpholine SCHEMBL11524539 | 0.84 | MEN1 (0.65) | KDM4EMEN1KMT2AGAACYP2C9 | |
| Succinic Acid SCHEMBL8731618 | 0.84 | LMNA (0.64) | KDM4EKMT2ALMNAEGLN1ALKBH5 | |
| Valeric Acid SCHEMBL8526265 | 0.83 | AKR1B1 (0.50) | KDM4EMEN1KMT2AGAACYP2C9 | |
| Malonic Acid SCHEMBL28388411 | 0.83 | MEN1 (0.50) | KDM4EMEN1KMT2AGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| CN-1950089-A | Morpholine compounds | PFIZER LTD (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
| US-3963730-A | ACID CATALYST | SANKYO COMPANY LIMITED (JA) | 1976-06-15 | — | — | US | disclosed |
| US-3959298-A | ACETONINE WITH WATER IN ACID CATALYST | SANKYO COMPANY LIMITED (JA) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | KDM4E 1680/4885MEN1 776/4885KMT2A 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.